Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

1708 ARTÍCULOS , VIENDO DEL 91 AL 105

Small Molecule Natural Products and Alzheimer's Disease

Wu X, Cai H, Pan L, Cui G, Qin F, Li Y, Cai Z.

Curr Top Med Chem. 2019;19(3):187-204. doi: 10.2174/1568026619666190201153257.

Homozygosity for the A431E mutation in PSEN1 presenting with a relatively aggressive phenotype

Parker J, Mozaffar T, Messmore A, Deignan JL, Kimonis VE, Ringman JM.

Neurosci Lett. 2019 Apr 23;699:195-198. doi: 10.1016/j.neulet.2019.01.047. Epub 2019 Feb 1.

Dysregulation of stress systems and nitric oxide signaling underlies neuronal dysfunction in Alzheimer's disease

Spiers JG, Chen HC, Bourgognon JM, Steinert JR.

Free Radic Biol Med. 2019 Apr;134:468-483. doi: 10.1016/j.freeradbiomed.2019.01.025. Epub 2019 Feb 2.

Expression of neurogenic markers in Alzheimer's disease: a systematic review and metatranscriptional analysis

Gatt A, Lee H, Williams G, Thuret S, Ballard C.

Neurobiol Aging. 2019 Apr;76:166-180. doi: 10.1016/j.neurobiolaging.2018.12.016. Epub 2019 Jan 8.

Therapeutic noninvasive brain stimulation in Alzheimer's disease and related dementias

Buss SS, Fried PJ, Pascual-Leone A.

Curr Opin Neurol. 2019 Apr;32(2):292-304. doi: 10.1097/WCO.0000000000000669.

Microglia in Alzheimer's disease: A target for immunotherapy

Wang S, Colonna M.

J Leukoc Biol. 2019 Jul;106(1):219-227. doi: 10.1002/JLB.MR0818-319R. Epub 2019 Feb 6.

Important advances in Alzheimer's disease from the use of induced pluripotent stem cells

Majolo F, Marinowic DR, Machado DC, Da Costa JC.

J Biomed Sci. 2019 Feb 6;26(1):15. doi: 10.1186/s12929-019-0501-5.

MicroRNAs for the Treatment of Dementia and Alzheimer's Disease

Maiese K.

Curr Neurovasc Res. 2019;16(1):1-2. doi: 10.2174/1567202616666190208094159.

Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease

Butterfield DA, Halliwell B.

Nat Rev Neurosci. 2019 Mar;20(3):148-160. doi: 10.1038/s41583-019-0132-6.

Scope of new formulation approaches in the repurposing of pioglitazone for the management of Alzheimer's disease

Jojo GM, Kuppusamy G.

J Clin Pharm Ther. 2019 Jun;44(3):337-348. doi: 10.1111/jcpt.12808. Epub 2019 Feb 9.

Tacrines for Alzheimer's disease therapy. III. The PyridoTacrines

de Los Ríos C, Marco-Contelles J.

Eur J Med Chem. 2019 Mar 15;166:381-389. doi: 10.1016/j.ejmech.2019.02.005. Epub 2019 Feb 4.

Microglial inflammation and phagocytosis in Alzheimer's disease: Potential therapeutic targets

Nizami S, Hall-Roberts H, Warrier S, Cowley SA, Di Daniel E.

Br J Pharmacol. 2019 Sep;176(18):3515-3532. doi: 10.1111/bph.14618. Epub 2019 May 11.

Transgenerational Interaction of Alzheimer's Disease with Schizophrenia through Amyloid Evolvability

Takamatsu Y, Ho G, Waragai M, Wada R, Sugama S, Takenouchi T, Masliah E, Hashimoto M.

J Alzheimers Dis. 2019;68(2):473-481. doi: 10.3233/JAD-180986.

Potential Astrocytic Receptors and Transporters in the Pathogenesis of Alzheimer's Disease

Zhang X, Lao K, Qiu Z, Rahman MS, Zhang Y, Gou X.

J Alzheimers Dis. 2019;67(4):1109-1122. doi: 10.3233/JAD-181084.

Neuroinflammation and fractalkine signaling in Alzheimer's disease

Finneran DJ, Nash KR.

J Neuroinflammation. 2019 Feb 11;16(1):30. doi: 10.1186/s12974-019-1412-9.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias